Advertisements
Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


Top 3 Ranked by Betweenness Centrality in Top 10 Influencers   Twitter Analytics by NodeXL for #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

 

www.worldmedicalinnovation.org

 

‘s Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World Forum comes to a close, here are TOP via ‘s Hashtags 🙏 to organizers for a stellar event & to all on for a robust conversation! 👏

 

Third Place in Top 10 Influencers 

  

 Tweets, N=152

 

SOURCE

https://nodexlgraphgallery.org/Pages/Graph.aspx?graphID=193125

 

#WMIF19_2019-04-09_09-37-27.xlsx

View an interactive version of this graph (experimental)

From:

Connected Action NodeXL-Reports

Uploaded on:

April 09, 2019

Short Description:

 

#WMIF19 via NodeXL http://bit.ly/2KB6cPN

@phsinnovation
@evankirstel
@aviva1950
@partnersnews
@beyondverbal
@dme_jun
@seemacms
@bwhihub
@massgovernor
@doylet

Top hashtags:
#wmif19
#ai
#healthcare
#artificialintelligence
#boston
#innovation
#wmif
#aiinpharma

Description:

 

Description

The graph represents a network of 731 Twitter users whose recent tweets contained “#WMIF19”, or who were replied to or mentioned in those tweets, taken from a data set limited to a maximum of 18,000 tweets. The network was obtained from Twitter on Tuesday, 09 April 2019 at 16:40 UTC.

The tweets in the network were tweeted over the 9-day, 18-hour, 32-minute period from Saturday, 30 March 2019 at 22:04 UTC to Tuesday, 09 April 2019 at 16:37 UTC.

Additional tweets that were mentioned in this data set were also collected from prior time periods. These tweets may expand the complete time period of the data.

There is an edge for each “replies-to” relationship in a tweet, an edge for each “mentions” relationship in a tweet, and a self-loop edge for each tweet that is not a “replies-to” or “mentions”.

The graph is directed.

The graph’s vertices were grouped by cluster using the Clauset-Newman-Moore cluster algorithm.

The graph was laid out using the Harel-Koren Fast Multiscale layout algorithm.

 

Highlighted in RED rankings for

@AVIVA1950

@pharma_BI

http://pharmaceuticalintelligence.com 

 

Top Influencers: Top 10 Vertices, Ranked by Betweenness Centrality

 

@phsinnovation
Smart Tweet

 

@evankirstel
Smart Tweet

 

@aviva1950
Smart Tweet

 

@partnersnews
Smart Tweet

 

@beyondverbal
Smart Tweet

 

@dme_jun
Smart Tweet

 

@seemacms
Smart Tweet

 

@bwhihub
Smart Tweet

 

@massgovernor
Smart Tweet

 

@doylet

 

Top URLs in Tweet in G3:

 

[3] https://www.fitzroyhealth.com/wmif
[2] https://worldmedicalinnovation.org/agenda/

[2] https://twitter.com/aviva1950/status/1115292614402695169 

[1] https://www.fda.gov/downloads/MedicalDevices/DigitalHealth/SoftwareasaMedicalDevice/UCM635052.pdf
[1] https://www.youtube.com/watch?v=AGhC864Wh-0

[1] https://www.youtube.com/watch?v=_wIO2EAM1xw

[1] https://twitter.com/happysylvie/status/1115639128455041025
[1] https://twitter.com/BayerUS/status/1114211171517784064
[1] https://twitter.com/BayerUS/status/1115245439173967872
[1] https://twitter.com/BayerPharma/status/1115259254003458049

 

Top Domains in Tweet in G2:

 

[26] twitter.com
[10] bwhclinicalandresearchnews.org
[6] worldmedicalinnovation.org
[5] linkedin.com
[2] lnkd.in
[1] connectwithpartners.org
[1] healthdatamanagement.com
[1] pharmaceuticalintelligence.com 
[1] youtube.com
[1] npr.org

 

Top Words in Tweet in G2:

 

[415] #wmif19
[236] phsinnovation
[163] #ai
[124] ai
[93] data
[91] dr
[82] care
[81] aviva1950 
[80] pharma_bi 
[78] healthcare

 

Top Mentioned in Entire Graph:

 

@phsinnovation
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@gehealthcare
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@evankirstel
Follow Smart Tweet

 

 

 

Top Mentioned in G1:

 

@phsinnovation
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@gehealthcare
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

@kieranmurphyceo
Follow Smart Tweet

 

@constancelehman
Follow Smart Tweet

 

@terribresenham
Follow Smart Tweet

 

@bayer
Follow Smart Tweet

 

Top Mentioned in G2:

 

@phsinnovation
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@partnersnews
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@massgeneralnews
Follow Smart Tweet

 

@bwhihub
Follow Smart Tweet

 

@chencao
Follow Smart Tweet

 

Top Mentioned in G5:

 

@evankirstel
Follow Smart Tweet

 

@phsinnovation
Follow Smart Tweet

 

@irmaraste
Follow Smart Tweet

 

@evirahealth
Follow Smart Tweet

 

@philips
Follow Smart Tweet

 

@aviva1950
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@health_xl
Follow Smart Tweet

 

@nvidia
Follow Smart Tweet

 

@edvaldez8888
Follow Smart Tweet

 

 

Top Domains in Tweet in G2:

 

[26] twitter.com
[10] bwhclinicalandresearchnews.org
[6] worldmedicalinnovation.org
[5] linkedin.com
[2] lnkd.in
[1] connectwithpartners.org
[1] healthdatamanagement.com
[1] pharmaceuticalintelligence.com 
[1] youtube.com
[1] npr.org

 

Top Words in Tweet in G2:

[415] #wmif19
[236] phsinnovation
[163] #ai
[124] ai
[93] data
[91] dr
[82] care
[81] aviva1950 
[80] pharma_bi 
[78] healthcare

 

Top Word Pairs in Tweet in Entire Graph:

 

[131] phsinnovation,#wmif19
[129] medical,innovation
[105] world,medical
[102] pharma_bi,aviva1950 
[101] innovation,forum
[59] #wmif19,phsinnovation
[55] looking,forward
[52] first,look
[51] jensen,huang
[47] #wmif19,evankristel

 

Top Word Pairs in Tweet in G1:

 

[36] phsinnovation,#wmif19
[23] innovation,forum
[22] world,medical
[22] medical,innovation
[20] #wmif19,phsinnovation
[20] nvidia,ceo
[19] jensen,huang
[18] pharma_bi,aviva1950 
[18] #wmif,#wmif19
[17] looking,forward

 

Top Word Pairs in Tweet in G2:

 

[77] pharma_bi,aviva1950 
[72] phsinnovation,#wmif19
[50] medical,innovation
[38] #wmif19,evankristel
[38] evankristel,pharma_bi 
[31] first,look
[30] today,s
[25] world,medical
[25] innovation,forum
[24] aviva1950,phsinnovation 

 

 

Top Replied-To in Entire Graph:

 

@phsinnovation
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@constancelehman
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@seemacms
Follow Smart Tweet

 

Top Replied-To in G2:

 

@phsinnovation
Follow Smart Tweet

 

@pharma_bi
Follow Smart Tweet

 

@massgovernor
Follow Smart Tweet

 

@brighamwomens
Follow Smart Tweet

 

@masseyeandear
Follow Smart Tweet
@landmaad
Follow Smart Tweet

 

@peterrchai
Follow Smart Tweet

 

@gilpress
Follow Smart Tweet

 

@nancyatheart
Follow Smart Tweet

 

@brighamresearch
Follow Smart Tweet

 

Download the Graph Data as a NodeXL Workbook

Download the Graph Data as GraphML

Download the NodeXL Options Used to Create the Graph

 

Advertisements

Read Full Post »


Tips on 280 Character Tweets on Twitter.com

 

The FIT members @LPBI Group are edified by the following advice and tips on TWEETING

 

From: Gail Thornton <gailsthornton@yahoo.com>

Reply-To: Gail Thornton <gailsthornton@yahoo.com>

Date: Saturday, March 2, 2019 at 5:33 PM

To: Rick Mandahl <rmandahl@gmail.com>, Amnon Danzig <amnon.danzig@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: In 280 Characters

Aviva:

Please let me offer some recommendations, suggestions and advice on how to compose tweets moving forward. These tips are a departure for how you currently compose and post tweets.

You need to find businesses, universities, research centers, who have a large number of followers (upwards of 500,000) and target them with your tweets.

Keep Tweets conversational.   Avoid business jargon when possible.

Think about how your content will be consumed by your followers. Would they want to retweet it or pass it along to others? Incorporate humor, inspiration and newsworthy content to draw followers in.

Twitter is particularly powerful at driving “amplification” for brand messages–retweets that share your message. In fact, 78% of user engagement with a brand’s Tweets is in the form of Retweets, This is essential in getting more people to read your tweets.

Tweets that contained more adverbs and verbs have a higher click-through rate than tweets with more nouns and adjectives. So the general rule that action words make for stronger, more compelling writing is also true for Tweets.

SUPER IMPORTANT: 

Consider creating a hashtag that is short, recognizable by followers, and allows them to easily follow along. If you’re using an existing hashtag, ensure you’re adding value to the conversation. The volume of hashtags is important as well: one or two hashtags can get you up to two times more engagement than tweets without hashtags (not 8-9-10), according to a study by Buddy Media/Salesforce.

There is usually a spike in retweets among those in the 71-100 character range—the “medium” length tweets column in this chart.   

 

Tweets with images received 18% more click-throughs, 89% more favorites, and 150% more retweets.

There is a 30% greater engagement rate when Tweets are published during the day (between 8AM-7PM). This makes sense if you consider the majority of news, store hours and activities happen during the day.

For example, a content calendar that you should adapt for LPBI. All businesses with Twitter accounts have a monthly content calendar that precisely and strategically lays out each day what you want to tweet. It is not a random act of tweeting that gets you noticed.

  • On Monday, you could launch a Twitter-only promotion for your followers. Tweet an online offer code or a secret word for customers to use when they visit your business.
  • On Tuesday, tweet a behind-the-scenes tour of your business. Highlight how your products are made or where they are sourced from.
  • On Wednesday: Create a regular series of Tweets that are informative or surprising such as tips.
  • On Thursday, retweet a few positive customer reviews. Or tweet some industry-related news your followers might find interesting.
  • Finally on Fridays, give customers a glimpse into your workplace culture. Tweet photos or Vine videos of your colleagues and employees hard at work or having fun.

Read Full Post »


Audio Podcasting @LPBI Group

Reporter: Aviva Lev-Ari, PhD, RN

 

On 3/9/2019 – Gail Thornton wrote:

The podcast idea is a good one if the content is unique to LPBI, which means podcasts need to created specifically for LBPI. Podcast ideas need to be created one per month, for example, and there  needs to be a calendar of them for the year with a specific person responsible for conducting it. 

Your aim is to get medical/scientific trade publications interested in retweeting your offerings — or interested in interviewing you or positioning LPBI and its key authors/writers as thought leaders on medical or scientific topics.

My idea: Anyone on the LPBI team can write a #ThoughtLeaderThursdays post for LinkedIn on a specific topic. These are creatively written brief articles on industry knowledge about a specific topic, current trends in science or insights into a scientific topic.

The posts are toughly 800-1,000 words. If anyone knows of a graphic designer, then a photo of the author can accompany the article along with a compelling graphic. Again, this is another way for others to share this post and for LPBI to develop a greater following of people

on social/digital media. On LinkedIn, type in #thoughtleaderthursdays and you’ll see examples. 

 

LinkedIn

LinkedIn

 

On 3/10/2019 – Dr. Williams wrote

Notes from book on Audio Podcasting

  1. Microphones -MOST important part is getting a good microphone
  2. Yeti by Blue Micorphone BEST
  3. Audiotechnia ATR BEST
  4. Logitech is OK but not best
  5. Test your microphones
  6. Test direction of microphone – above your mouth produces a nasal sound. Microphone at your throat produces too much bass
  7. Test microphone distance – SPEAK in NORMAL voice then adjust the GAIN later. Note: Skype does a good job auto-adjusting the gain so don’t worry while conducting interviews about Gain issues
  8. Get good headphones
  9. Eliminates background noise. Get good headphones like BEATS STUDIO which will detect any background noise during recording.

*** NOTE if doing a co-host podcast USE SKYPE

  1. Recording on Skype
  2. Record using either the Pamela or Call recorder Program. ALWAYS CHOOSE .wav format, never .mp3 format because . wav has higher quality
  3. EDITING -probably the SECOND MOST IMPORTANT PROCESS. There are three suggested audio editing software programs
  4. Audacity – this is a FREE program
  5. Adobe Audition – very good but $300
  6. If you have a Macintosh or Apple it comes with Garageband, a very good audio editing software
  7. Hosting
  8. If uploading a weekly show you will need a hosting site with at least 125 MB capacity per month
  9. If using WORDPRESS use the plugin Blubrry Power Press: lets you easily put in your audiopodcast
  10. Upload to itunes – it takes a week but they will give you a URL so you can put it on your blog site

 

  • On 3/9/2019 – Aviva posted

Top 10 CRISPR Podcasts Every Scientist (& Non-Scientist) by Synthego.com

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/03/09/top-10-crispr-podcasts-every-scientist-non-scientist-by-synthego-com/

  • On 3/12/2015 – Dr. Williams posted

Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup

Reporter: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2015/03/12/podcast-review-quiet-innovation-podcast-on-obtaining-for-your-startup/

 

  • On 1/25/2016 – Aviva posted

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

 

  • On 3/17/2016 – Aviva posted

CRISPR: A Podcast from Nature.com on Gene Editing

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/

 

We are inspired by

Browse podcasts, programs, news, features and in-depth coverage from Boston’s NPR news station.

https://www.wbur.org/programs

 

WBUR Programs And Podcasts

Morning Edition

Stories and commentaries that inform, challenge and occasionally…

On Point

Go behind the headlines: From the economy and…

Here & Now

NPR and WBUR’s live midday news program

Radio Boston

Provocative stories and authentic voices from around Boston

All Things Considered

News, interviews, commentaries, reviews and offbeat features

Only A Game

An award-winning weekly sports magazine hosted by veteran…

Modern Love

Modern Love features top actors performing true stories…

Dear Sugars

Radically empathic advice

Endless Thread

The front page of the Internet–also known as…

Last Seen

It remains the most valuable — and confounding…

Circle Round

Thoughtfully-selected folktales from around the world are adapted…

Kind World

Kind World is a show about compassion from…

Magic Pill

A daily dose of get-up-and-go

Edge of Fame

An exploration of the life that happens before,…

Season Ticket

Season Ticket is full of engaging talk, insightful…

Freak Out and Carry On

Freak Out and Carry On, WBUR’s politics and…

WBUR Sections

WBUR News

Local news coverage from WBUR

Cognoscenti

Thinking That Matters

CommonHealth

News and smart analysis on all things health

The ARTery

Arts | Culture | Boston

Bostonomix

The stories behind the Boston area’s innovation economy

Edify

Education: preschool to grad school

The Remembrance Project

Ordinary people who lived extraordinary lives

The Wild Life

Covering animal issues around the world

Open Source

An American conversation with global attitude

Special Projects

Recent special reports and series from WBUR’s newsroom

Read Full Post »


Top 10 CRISPR Podcasts Every Scientist (& Non-Scientist) by Synthego.com

Reporter: Aviva Lev-Ari, PhD, RN

 

 

  • On 3/12/2015 – Dr. Williams posted

Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup

Reporter: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2015/03/12/podcast-review-quiet-innovation-podcast-on-obtaining-for-your-startup/

 

  • On 1/25/2016 – I posted

Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

 

  • On 3/17/2016 – I posted

CRISPR: A Podcast from Nature.com on Gene Editing

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/

 

 

Download eBook


CRISPR 101

CRISPR has ignited a revolution. Although it’s a relatively recent discovery in the history of biotechnology, CRISPR has quickly become a standard laboratory tool. This comprehensive CRISPR 101 eBook is designed to ease any scientist into the world of CRISPR by providing an overview of its fundamentals.

Download

Download eBook


CRISPR 101

CRISPR has ignited a revolution. Although it’s a relatively recent discovery in the history of biotechnology, CRISPR has quickly become a standard laboratory tool. This comprehensive CRISPR 101 eBook is designed to ease any scientist into the world of CRISPR by providing an overview of its fundamentals.

Download

SOURCE

https://www.synthego.com/blog/10-podcasts-every-crispr-scientist-will-love

Read Full Post »


Royalties in Kindle Unlimited and Kindle Owners’ Lending Library – A guide to publishing on Amazon

 

Royalties in Kindle Unlimited and Kindle Owners’ Lending Library

You’re eligible for royalty payment from Kindle Unlimited (KU, or Abonnement Kindle in France) and the Kindle Owners’ Lending Library (KOLL) for pages an individual customer reads in your book for the first time. A guide to publishing on Amazon

A customer can read your book as many times as they like, but we will only pay you for the number of pages read the first time the customer reads them. It may take months for customers to read pages in your book, but no matter how long it takes, we’ll still pay you once it happens. This is true even if your KDP Select enrollment period has expired, and you choose not to re-enroll.

Kindle Edition Normalized Page Count (KENPC v3.0)

To determine a book’s page count in a way that works across genres, devices, and display settings, we developed the Kindle Edition Normalized Page Count (KENPC). KENPC is calculated using standard formatting settings (font, line height, line spacing, etc.). We use KENPC to measure the number of pages customers read in your book, starting with the Start Reading Location (SRL) to the end of your book. Amazon typically sets SRL at chapter 1 so readers can start reading the core content of your book as soon as they open it. Non-text elements within books including images, charts and graphs will count toward a book’s KENPC.

KENPC v3.0
We released KENPC v3.0 to improve the way we measure how many pages of each book Kindle Unlimited and KOLL customers read. We’re constantly working to improve our programs and increase fairness of how we allocate the KDP Select Global Fund. These changes continue to improve the program and reward authors whose books are being borrowed and read the most by customers.

The KENPC v3.0 update applies uniformly to all KDP Select books and all versions of those books. Regardless of which version a customer may be reading, all future royalties will be paid using KENPC v3.0. If a customer previously borrowed your book and is still reading it, any new pages read will be based on KENPC v3.0.

Authors are able to earn a maximum of 3,000 Kindle Edition Normalized Pages (KENPs) read per title per customer. This means that each time your book is borrowed and read, you will receive credit for up to 3,000 pages. We believe this results in an equitable distribution of the KDP Select Global Fund.

Your book’s KENPC
You can see your book’s KENPC v3.0 listed on the “Promote and Advertise” page in your Bookshelf, and you can also see total pages read on your Sales Dashboard report. Because it’s based on default settings, KENPC v3.0 may vary from page counts listed on your Amazon detail page, which are derived from other sources.

KDP Select Global Fund
Our total payout from the KDP Select Global Fund will be unaffected by the transition to KENPC v3.0, and the amount you earn from the global fund will continue to be determined based on your share of total pages read by Kindle Unlimited (KU) and Kindle Owners’ Lending Library (KOLL) customers. The new KENPC version will be applied uniformly to all KDP Select books and used to measure all pages read.

 

Royalties

You’ll get one combined royalty payment for both KU and KOLL, paid according to the same payment schedule and payment method you selected for your other KDP sales.We review the size of the KDP Select Global Fund each month in order to make it compelling for authors to enroll their books in KDP Select. We announce the fund monthly in our community forum on kdp.amazon.com.The share of fund allocated to each country varies based on a number of factors, such as exchange rates, customer reading behavior, and local subscription pricing. Author earnings are then determined by their share of total pages read, up to a total of 3,000 pages per customer per title.

For example, here’s how we’d calculate royalty payout if $10 million in funds were available in a given month with 100 million total pages read (Note: Actual payouts vary and may be less; check your Prior Month’s Royalty Report to see your earnings):

  • Author with a 100 page bookthat was borrowed and read completely 100 times would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed and read completely 100 times would earn $2,000 ($10 million multiplied by 20,000 pages for this author divided by 100,000,000 total pages).
  • Author of a 200 page bookthat was borrowed 100 times but only read halfway through on average would earn $1,000 ($10 million multiplied by 10,000 pages for this author divided by 100,000,000 total pages).

We always support our authors’ efforts to promote their books, but at the same time we work to prevent any manipulation of the Kindle platform.

We do not permit authors to offer, or participate in marketing that incentivizes Kindle Unlimited or Kindle Owners’ Lending Library customers to read their books in exchange for compensation of any kind. This includes payment (whether in the form of money or gift certificates), bonus content, entry to a contest or sweepstakes, discounts on future purchases, extra product, or other gifts.

Because we’re always looking to improve our authors’ experience, we have systems in place to monitor for potential manipulation.

 

Reporting

You can see your Kindle Edition Normalized Pages (KENP) Read in your Sales Dashboard report by marketplace and title. To see historical pages read, click “Generate Report” from your Sales Dashboard and go to the Orders Report tab.

If you’re enrolled in KDP Select, you will also see the following data on your reports:

Month-To-Date Unit Sales Report: The number of pages Kindle Unlimited or KOLL customers read of your books, under the “Kindle Edition Normalized Pages (KENP) Read” column.

Prior Months’ Royalties Report: For every title, there are five possible transaction types:

  • 35%:Amount a title earned under the 35% royalty option

  • 70%:Amount a title earned under the 70% royalty option

  • KDP Select Units:Amount every KDP Select-enrolled title earned monthly through Kindle Unlimited (KU) and the Kindle Owners’ Lending Library (KOLL). If a customer reads pages in your book for the first time through KU or KOLL, you will see a separate line item indicating the accumulated number of pages read under the column “Kindle Edition Normalized Pages (KENP) Read,” and the royalty earned through KU and KOLL under the “Royalty” column.

  • Free – Promotion:Free downloads due to Free promotion campaign(s) through KDP Select.

  • Free – Price Match:Free downloads due to competitor free price match.

 

SOURCE:  https://kdp.amazon.com/en_US/help/topic/G201541130

Read Full Post »


eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

Author: Aviva Lev- Ari, PhD, RN

 

Six demonstrations that justify the claims made in our 2019 VISION:

https://pharmaceuticalintelligence.com/vision/

  • Point #1: Top Author, Chief Scientific Officer, MD, FCAP – share in the Journal’s archive computed
  • Point #2: Top authors by e-Readers per article – A Team at work
  • Point #3: Team members Led by Key Opinion Leader [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes
  • Point #4: Functions and Forms by Asset Class
  • Point #5: SYNERGY among the Three Asset Classes stimulates Value Creation
  • Point #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

 

POINT #1: Top Author, Chief Scientific Officer, a retired Chief of Pathology, LHB, MD, FCAP – share in the Journal’s archive computed

Journal archive has 5,486 articles published

LHB has published 1,390 articles = 25.33% – he joined our team with a publication list of +200 articles in referred academic journals. LHB is co-curator of many articles with many of the team members

  • The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy– The Best Writers Among the WRITERS

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

 

POINT #2: Top authors by e-Readers per article – A Team at work

Click on this link to review the contributions of Team members who’s articles achieved >1,000 Views.

  • Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/2019/01/30/article-title-author-curators-name-and-article-views-1000-4-2012-1-2018-pharmaceuticalintelligence-com/

 

POINT #3: Team members led by Key Opinion Leader (KOL) [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes

 

List of LPBI IP Assets by Asset Class representing a Team Effort

 

  • IP Asset Class I: Launched Open Access Online Scientific Journal @com, 4/2012

https://lnkd.in/erfbayJ

  •  IP Asset Class II: Launched BioMed eSeries, 16-Volumes in Life Sciences and Medicine, 10/2012

BioMed e-Series: 16 Volumes – electronic Table of Contents (eTOCs) of each Volume

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/


Launched 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515

https://lnkd.in/e6WkMgF

Launched 10 Volumes in Medicine: Genomics 1,2  Cancer 1,2 Immunology 1,2,3  Precision Medicine 1,2,3,4

https://lnkd.in/ekWGNqA

 

  • IP Asset Class III: Launched Real Time Press Coverage of Biotech Conferences, 3/2013

https://pharmaceuticalintelligence.com/press-coverage/

Part One: The Process of Real Time Coverage using Social Media

Part Two: List of BioTech Conferences 2013 to Present

Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

 

POINT #4: FUNCTIONS and FORMS by ASSET CLASS

 

LPBI Group’s IP:VENTURE’s Future Potential
IP Asset Class I
https://lnkd.in/erfbayJ
IP Asset Class II
https://lnkd.in/ekWGNqA
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Open Access Journal– M1.5 e-Readers,- 5.5K articles- 670 categories,- 7.3K comments- 10K Tags
BioMed E-Series– 16 Volumes- 5 Specialties in Medicine- 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515https://lnkd.in/e6WkMgF
Real Time Coverage BioTech/Medicine Conferences– eProceedings- Real Time Tweets on- Two Twitter Handles- Conference Hash Tags@pharma_BI@AVIVA1950- Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’sLeadership:- Senior Editors- Our Team
Our Team’s Product
https://pharmaceuticalintelligence.com/contributors-biographies/
Senior Editors’ Product with Our Team
https://pharmaceuticalintelligence.com/contributors-biographies/senior-editors/https://pharmaceuticalintelligence.com/contributors-biographies/
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
Architecture   Methodologies for ourPlatforms
·       Multi-Authoring Platform – wordpress.com·       Authoring Privilege levels·       Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture·       Generation of new categories by authors developing the categories they are Owners of·       Article update policy
·       eTOCs design by Editors·       e-Book Style uniformity across all eSeries·       Structure of eBook Parts·       Structure of Chapters·       Structure of Articles·       Commission of Articles Specifically for given e-Books by Editor-in-Chief·       Overarching guidance for e-Books within each eSeries and across eSeries
·       Part One: The Process of Real Time Coverage using Social Media·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA·       Template Development Process·       Channels of Social Media Development
Business ModelDevelopment: Content Creation by Curation of Scientific Findings
·       Author/Curator initiated article·       Article Commissions by Editor-in-Chief·       Co-Curations·       Research Category Ownership·       e-Books Editors role defined (Job description)
·       e-Books in Kindle Store·       30,000 Oncologists in the US·       40,000 Cardiologists in the US·       All Primary Care Physicians·       All Medical Schools for Curriculum development·       Global market for Medical EducationALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515https://lnkd.in/e6WkMgF@Amazon UNBUNDLED 10 Volumeshttps://lnkd.in/ekWGNqA·       Genomics 1,2 ($190)·       Cancer 1,2 ($175)·       Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)·       Precision Medicine 1,2,3,4 ($274)
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.·       Digital Archive of Conferences eProceedingsPart Three: Conference eProceedings DELIVERABLES & Social Media Analytics
 
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Real Time Coverage BioTech/Medicine Conferences
– eProceedings
– Real Time Tweets on
– Two Twitter Handles
– Conference Hash Tags
@pharma_BI
@AVIVA1950
Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
·       Part One: The Process of Real Time Coverage using Social Media
·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA
·       Template Development Process
·       Channels of Social Media Development
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
·       Digital Archive of Conferences eProceedings
Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

POINT #4 (IN DETAIL): Functions and Forms by Asset Class

 

IP Asset Class I: The Journal

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

>> Evolution of Platform Architecture Methodologies: 

  • Multi-Authoring Platform – wordpress.com
  • Authoring Privilege levels
  • Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture
  • Generation of new categories by authors developing the categories they are Owners of
  • Article update policy

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • Author/Curator initiated article
  • Article Commissions by Editor-in-Chief
  • Co-Curations
  • Research Category Ownership
  • e-Books Editors role defined (Job description)

 

IP Asset Class II: BioMed e-Series

 

> Evolution of Platform Architecture Methodologies

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

  • eTOCs design by Editors
  • e-Book Style uniformity across all eSeries
  • Structure of eBook Parts
  • Structure of Chapters
  • Structure of Articles
  • Commission of Articles Specifically for given e-Books by Editor-in-Chief
  • Overarching guidance for e-Books within each eSeries and across eSeries

 

> Intellectual Property Development (Content Creation by Curation) Business Model 

 

  • e-Books in Kindle Store
  • 30,000 Oncologists in the US
  • 40,000 Cardiologists in the US
  • US & Global markets for Cardiology, Genomics, Cancer, Immunology, Infectious Diseases, Precision Medicine
  • All Primary Care Physicians
  • All Medical Schools for Curriculum development
  • Global market for Medical Education

 

ALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]

@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515 https://lnkd.in/e6WkMgF

@Amazon UNBUNDLED 10 Volumes in #Medicine https://lnkd.in/ekWGNqA

  • Genomics 1,2 ($190)
  • Cancer 1,2 ($175)
  • Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)
  • Precision Medicine 1,2,3,4 ($274)

 

Series A – Cardiovascular Diseases – 6 volumes $515

 

Series B – Genomics 1,2  – 2 volumes $190

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On comsince 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Volume 2 is Work-in-Progress To Be Published in 6/2019 at $115

 

Series C – Cancer & Oncology $175 

  • VOLUME 1 Cancer Biology Genomics

http://www.amazon.com/dp/B013RVYR2K

  • VOLUME 2 Therapies Genomics Interventional Immunotherapy Nanotechnology in Drug Delivery

http://www.amazon.com/dp/B071VQ6YYK

 

Series D – Metabolomics, Immunology, Infectious Diseases $190

  • VOLUME 1 Metabolomics

http://www.amazon.com/dp/B012BB0ZF0

  • VOLUME 2 Infectious Diseases & VOLUME 3 Immunology

https://www.amazon.com/dp/B075CXHY1B

 

Series E Precision Medicine – Four Volumes, Volumes 1,2,3,4 at $274

  • Patients Voices

https://www.amazon.com/dp/B076HGB6MZ

  • Physiology and Therapeutics

https://www.amazon.com/dp/B078313281

  • Medical Discoveries: Genomics Therapeutics

http://www.amazon.com/dp/B019VH97LU

  • 3D #BioPrinting in Medicine for Precision Medicine

https://www.amazon.com/dp/B078QVDV2W

 

IP Asset Class III: Real Time Coverage of BioTech Conferences

 

>> Evolution of Platform Architecture Methodologies

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

  • Template Development Process
  • Channels of Social Media Development

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
  • Digital Archive of Conferences eProceedings

 

POINT #5: SYNERGY among the Three Asset Classes stimulates Value Creation

 

  • Concepts from +60 Conferences I covered yielded ~300 new articles, five new per conference, at least
  • Electronic Table of Contents [eTOCs] for each e-Book of the [1,2,3..,16] is derived from the Research categories of the Journal
  • Journal Ontology has 700 Research Categories – knowledge architecture designed by experts
  • Every article in the Journal is connected with Social Media Icons on wordpress.com as an engine for
  1. Pingbacks
  2. New eReaders
  3. Scientists applying to author for the Journal
  4. +7,300 Scientific comments on 5,486 articles published – AGORA  

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

 

POINT #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

Work-in-Progress

 

 

Other related articles published in this Open Access Online Scientific Journal include the following: 

 

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

 

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

@PharmaceuticalIntelligence.com – A Case Study on the LEADER in Curation of Scientific Findings

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

 

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://pharmaceuticalintelligence.com/2016/08/15/curation-of-scientific-content-leaders-in-pharmaceutical-business-intelligence-lpbi-group-boston/

 

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/

 

Cardiovascular Diseases and Pharmacological Therapy: Curations by Aviva Lev-Ari, PhD, RN, 2006 – 4/2018

https://pharmaceuticalintelligence.com/2014/04/17/cardiovascular-diseases-and-pharmacological-therapy-curations-by-aviva-lev-ari-phd-rn/

 

Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

 

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

 

 

 

 

Read Full Post »


Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Expert, Author, Writer’s Initials

Name & Bio

Roles

@LPBI Group

LHB Larry Bernstein, MD, FACP,

 

Member of the Board

Expert, Author, Writer – All Specialties of Medicine & Pathology

Content Consultant to Series B,C,D,E

Editor, Series D, Vol. 1, Series E, Vols 2,3,

Co-Editor – BioMed E-Series 13 of the 16 Vols

JDP Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC,

 

Expert, Author, Writer, All Specialties of Medicine, Cardiology and Cardiac Imaging

Content Consultant for SERIES A, Cardiovascular Diseases Co-Editor: Vols 2,3,4,5,6

ALA Aviva Lev-Ari, PhD, RN,

-Ex – SRI, Int’l

-Ex – MITRE

-Ex – McGraw-Hill

Director and Founder

Editor-in-Chief, @pharmaceuticalintelligence.com

Methodologies Developer:

  • Journal Platform Architect,
  • CURATION of Scientific Findings Modules,
  • REALTIME eProceedings Digital 1-Click Publishing

Expert, Author, Writer:

  • Analytics
  • Molecular Cardiology
  • Vascular Biology
TB Tilda Barliya, PhD,

@BIU

Expert, Author, Writer: Nanotechnology for Drug Delivery

Co-Editor, Series C, Vols. 1,2

DN Dror Nir, PhD,

 

Expert, Author, Writer: Cancer & Medical Imaging Algorithms
ZR       
Ziv Raviv, PhD,
@Technion
Expert, Author, Writer: Biological Sciences, Cancer
ZS Zohi Sternberg, PhD, Expert, GUEST Author, Writer

 

Expert, GUEST Author, Writer

Neurological Sciences

SJW Stephen J. Williams, PhD Pharmacology, BSc Toxicology

Ex-Fox Chase

EAW – Cancer Biology

Co-Editor, Series A, Vol.1

Co-Editor, Series B, Genomics: Vols. 1,2

Co-Editor, Series C, Cancer, Vols. 1,2

DS Demet Sag, PhD, CRA, GCP,

 

Expert, Author, Writer: Genome Biology, Immunology, Biological Sciences: Cancer
SS Sudipta Saha, PhD,

 

Expert, Author, Writer: Reproductive Biology, Endocrinology, Bio-Instrumentation

Co-Editor, Series D, Volume 2, Infectious Diseases

AV Aviral Vatsa, PhD, MBBS

 

Expert, Author, Writer: Medical Sciences, Bone Disease, Human Sensation and Cellular Transduction: Physiology and Therapeutics

 

RS Ritu Saxena, PhD,

 

Expert, Author, Writer: Biological Sciences, Bone Disease, Cancer (Lung, Liver)
GST Gail S. Thornton, PhD(c),

Ex-MERCK

Contributing Editor, Author and Medical Writer

Co-Editor, Series E, Vol.1 Voices of Patients

RN Raphael Nir, PhD, MSM, MSc

Ex-ScheringPlough

– Expert, Author, Writer – Member of the Cancer Research Team: Brain Cancer, Liver Cancer, Cytokines

– CSO, SBH Sciences, Inc.

MB Michael R. Briggs, Ph.D.

Ex-Pfizer

– Expert, Author, Writer – Member of the Cancer Research Team: NASH

– CSO, Woodland Biosciences

AK Alan F. Kaul, R.Ph., Pharm.D, M.Sc., M.B.A., FCCP, Expert, Author, Writer

Ex-Director BWH Pharmacy

Expert, Author, Writer: Pharmacology – all aspects of Drug development and dispensation, Policy analyst
AS Anamika Sarkar, PhD,

 

Expert, Author, Writer: Computation Biology & Bioinformatics
MWF Marcus Feldman, PhD,

Stanford University, Biological Sciences, Center for Genomics

751
Research items
51,402
Reads
39,126
Citations
Member of the Board,

Scientific Counsel: Life Sciences,

Content Consultant Series B, Genomics, Vols. 1,2

Co-Editor, Vol. 2, NGS

 

Article Title and Views >1,000,

4/2012 – -1/2018

 

 

 

 

Home page / Archives

Authors

Curators

Reporters

by Name

 

Views

by 

eReaders

 

 

 

 

 

600,145

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? LHB 16,720
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

JDP

ALA

13,225
Paclitaxel vs Abraxane (albumin-bound paclitaxel) TB 11,872
Recent comprehensive review on the role of ultrasound in breast cancer management DN 11,715
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care ALA 7,045
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications ALA 6,435
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) TB 6,309
Our TEAM ALA 6,213
Akt inhibition for cancer treatment, where do we stand today? ZR 4,744
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects LHB 4,508
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses ZS 4,188
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation SJW 4,128
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad DS 3,678
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets LHB 3,652
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules SJW 3,625
Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms Multiple

Authors

3,575
Interaction of enzymes and hormones SS 3,546
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo SJW 3,403
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging DN 3,399
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology TB 3,371
Founder ALA 3,363
BioMed e-Series ALA 3,246
Signaling and Signaling Pathways LHB 3,178
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment SS 3,044
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community

JDP

LHB

ALA

3,034
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Dr. Karra 3,016
VISION ALA 2,988
Targeting the Wnt Pathway [7.11] LHB 2,961
Bone regeneration and nanotechnology AV 2,922
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) ALA 2,892
The History and Creators of Total Parenteral Nutrition LHB 2,846
Funding, Deals & Partnerships ALA 2,708
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) TB 2,700
LIK 066, Novartis, for the treatment of type 2 diabetes LHB 2,693
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® ALA 2,606
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation LHB 2,579
Nitric Oxide and Platelet Aggregation Dr. Karra 2,550
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) LHB 2,549
Isoenzymes in cell metabolic pathways LHB 2,535
“The Molecular pathology of Breast Cancer Progression” TB 2,491
In focus: Circulating Tumor Cells RS 2,465
Nitric Oxide Function in Coagulation – Part II LHB 2,444
Monoclonal Antibody Therapy and Market DS 2,443
Update on FDA Policy Regarding 3D Bioprinted Material SJW 2,410
Journal PharmaceuticalIntelligence.com ALA 2,340
A Primer on DNA and DNA Replication LHB 2,323
Pyrroloquinoline quinone (PQQ) – an unproved supplement LHB 2,294
Integrins, Cadherins, Signaling and the Cytoskeleton LHB 2,265
Evolution of Myoglobin and Hemoglobin LHB 2,251
DNA Structure and Oligonucleotides LHB 2,187
Lipid Metabolism LHB 2,176
Non-small Cell Lung Cancer drugs – where does the Future lie? RS 2,143
Biosimilars: CMC Issues and Regulatory Requirements ALA 2,101
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research SJW 2,092
About ALA 2,076
Sex Hormones LHB 2,066
CD47: Target Therapy for Cancer TB 2,041
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes ALA 2,017
Swiss Paraplegic Centre, Nottwil, Switzerland – A World-Class Clinic for Spinal Cord Injuries GST 1,989
Introduction to Tissue Engineering; Nanotechnology applications TB 1,964
Problems of vegetarianism SS 1,940
The History of Infectious Diseases and Epidemiology in the late 19th and 20th Century LHB 1,817
The top 15 best-selling cancer drugs in 2022 & Projected Sales in 2020 of World’s Top Ten Oncology Drugs ALA 1,816
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node TB 1,812
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands ALA 1,809
Wnt/β-catenin Signaling [7.10] LHB 1,777
The role of biomarkers in the diagnosis of sepsis and patient management LHB 1,766
Neonatal Pathophysiology LHB 1,718
Nanotechnology and MRI imaging TB 1,672
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions JDP

ALA

1,659
Ultrasound-based Screening for Ovarian Cancer DN 1,655
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases JDP 1,653
Scientific and Medical Affairs Chronological CV ALA 1,619
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) ALA 1,609
Stenting for Proximal LAD Lesions ALA 1,603
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? JDP

ALA

1,602
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) LHB 1,597
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB LHB 1,588
Diet and Diabetes LHB 1,572
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? ALA 1,546
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays LHB 1,540
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers ALA 1,534
Altitude Adaptation LHB 1,527
Baby’s microbiome changing due to caesarean birth and formula feeding SS 1,498
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin ALA 1,488
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes ALA 1,476
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase DS 1,469
CRISPR/Cas9: Contributions on Endoribonuclease Structure and Function, Role in Immunity and Applications in Genome Engineering LHB 1,468
Cancer Signaling Pathways and Tumor Progression: Images of Biological Processes in the Voice of a Pathologist Cancer Expert LHB 1,452
Signaling transduction tutorial LHB 1,443
Diagnostic Evaluation of SIRS by Immature Granulocytes LHB 1,440
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack ALA 1,426
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease ALA 1,424
Nanotechnology and Heart Disease TB 1,419
Aviva Lev-Ari, PhD, RN, Director and Founder ALA 1,416
Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects LHB 1,415
Nitric Oxide and it’s impact on Cardiothoracic Surgery TB 1,405
A New Standard in Health Care – Farrer Park Hospital, Singapore’s First Fully Integrated Healthcare/Hospitality Complex GST 1,402
Mitochondrial Damage and Repair under Oxidative Stress LHB 1,398
Ovarian Cancer and fluorescence-guided surgery: A report TB 1,395
Sex determination vs. Sex differentiation SS 1,393
LPBI Group ALA 1,372
Closing the Mammography gap DN 1,368
Cytoskeleton and Cell Membrane Physiology LHB 1,367
Crucial role of Nitric Oxide in Cancer RS 1,364
Medical 3D Printing ALA 1,332
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty LHB 1,325
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments LHB 1,310
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism

LHB

JDP

ALA

1,301
Mitochondrial Dynamics and Cardiovascular Diseases RS 1,284
Nitric Oxide and Immune Responses: Part 2 AV 1,282
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors SJW 1,269
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells using a bacterial CRISPR/Cas ALA 1,261
Autophagy LHB 1,255
Mitochondrial fission and fusion: potential therapeutic targets? RS 1,246
Summary of Lipid Metabolism LHB 1,239
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function LHB 1,233
Future of Calcitonin…? Dr. Karra 1,211
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery ALA 1,197
Gamma Linolenic Acid (GLA) as a Therapeutic tool in the Management of Glioblastoma

RN

MB

1,193
Nanotechnology and HIV/AIDS Treatment TB 1,181
Patiromer – New drug for Hyperkalemia ALA 1,179
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly ALA 1,177
A Patient’s Perspective: On Open Heart Surgery from Diagnosis and Intervention to Recovery Guest Author: Ferez S. Nallaseth, Ph.D. 1,173
Assessing Cardiovascular Disease with Biomarkers LHB 1,167
Development Of Super-Resolved Fluorescence Microscopy LHB 1,166
Ubiquitin-Proteosome pathway, Autophagy, the Mitochondrion, Proteolysis and Cell Apoptosis: Part III LHB 1,162
Atrial Fibrillation contributing factor to Death, Autopsy suggests CEO Dave Goldberg had heart arrhythmia before death ALA 1,159
Linus Pauling: On Lipoprotein(a) Patents and On Vitamin C ALA 1,156
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation ALA 1,154
The History of Hematology and Related Sciences LHB 1,151
Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin SJW 1,146
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents AV 1,143
Imatinib (Gleevec) May Help Treat Aggressive Lymphoma: Chronic Lymphocytic Leukemia (CLL) ALA 1,140
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing SJW 1,137
New England Compounding Center: A Family Business AK 1,120
EpCAM [7.4] LHB 1,113
Amyloidosis with Cardiomyopathy LHB 1,110
Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification. SJW 1,095
Acoustic Neuroma, Neurinoma or Vestibular Schwannoma: Treatment Options ALA 1,089
Treatment of Refractory Hypertension via Percutaneous Renal Denervation ALA 1,088
Proteomics – The Pathway to Understanding and Decision-making in Medicine LHB 1,085
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model AS 1,085
Pancreatic Cancer: Genetics, Genomics and Immunotherapy TB 1,083
A NEW ERA OF GENETIC MANIPULATION   DS 1,075
Targeting Mitochondrial-bound Hexokinase for Cancer Therapy ZR 1,074
Normal and Anomalous Coronary Arteries: Dual Source CT in Cardiothoracic Imaging JDP

ALA

1,062
Transdermal drug delivery (TDD) system and nanotechnology: Part II TB 1,057
Lung Cancer (NSCLC), drug administration and nanotechnology TB 1,046
Pharma World: The Pharmaceutical Industry in Southeast Asia – Pharma CPhI 20-22 March, 2013, Jakarta International Expo, Jakarta, Indonesia ALA 1,045
Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options LHB 1,044
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I AV 1,044
Press Coverage ALA 1,036
Carbohydrate Metabolism LHB 1,036
Open Abdominal Aortic Aneurysm (AAA) repair (OAR) vs. Endovascular AAA Repair (EVAR) in Chronic Kidney Disease Patients – Comparison of Surgery Outcomes LHB

ALA

1,032
In focus: Melanoma Genetics RS 1,018
Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD ALA 1,015
Medical Devices Start Ups in Israel: Venture Capital Sourced Locally – Rainbow Medical (GlenRock) & AccelMed (Arkin Holdings) ALA 1,007
The Development of siRNA-Based Therapies for Cancer ZR 1,003

Other related articles published in this Open Access Online Scientific Journal include the following:

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

Read Full Post »

« Newer Posts - Older Posts »